Literature DB >> 21471228

Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice.

Kate L Stokes1, Michael H Chi, Kaori Sakamoto, Dawn C Newcomb, Michael G Currier, Matthew M Huckabee, Sujin Lee, Kasia Goleniewska, Carla Pretto, John V Williams, Anne Hotard, Taylor P Sherrill, R Stokes Peebles, Martin L Moore.   

Abstract

Airway mucus is a hallmark of respiratory syncytial virus (RSV) lower respiratory tract illness. Laboratory RSV strains differentially induce airway mucus production in mice. Here, we tested the hypothesis that RSV strains differ in pathogenesis by screening six low-passage RSV clinical isolates for mucogenicity and virulence in BALB/cJ mice. The RSV clinical isolates induced variable disease severity, lung interleukin-13 (IL-13) levels, and gob-5 levels in BALB/cJ mice. We chose two of these clinical isolates for further study. Infection of BALB/cJ mice with RSV A2001/2-20 (2-20) resulted in greater disease severity, higher lung IL-13 levels, and higher lung gob-5 levels than infection with RSV strains A2, line 19, Long, and A2001/3-12 (3-12). Like the line 19 RSV strain, the 2-20 clinical isolate induced airway mucin expression in BALB/cJ mice. The 2-20 and 3-12 RSV clinical isolates had higher lung viral loads than laboratory RSV strains at 1 day postinfection (p.i.). This increased viral load correlated with higher viral antigen levels in the bronchiolar epithelium and greater histopathologic changes at 1 day p.i. The A2 RSV strain had the highest peak viral load at day 4 p.i. RSV 2-20 infection caused epithelial desquamation, bronchiolitis, airway hyperresponsiveness, and increased breathing effort in BALB/cJ mice. We found that RSV clinical isolates induce variable pathogenesis in mice, and we established a mouse model of clinical isolate strain-dependent RSV pathogenesis that recapitulates key features of RSV disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21471228      PMCID: PMC3126300          DOI: 10.1128/JVI.01693-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  75 in total

Review 1.  Respiratory syncytial virus and parainfluenza virus.

Authors:  C B Hall
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

2.  Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges, and mortality.

Authors:  T S Howard; L H Hoffman; P E Stang; E A Simoes
Journal:  J Pediatr       Date:  2000-08       Impact factor: 4.406

3.  Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection.

Authors:  J J Anderson; J Norden; D Saunders; G L Toms; R Scott
Journal:  J Gen Virol       Date:  1990-07       Impact factor: 3.891

4.  IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent.

Authors:  K K Tekkanat; H F Maassab; D S Cho; J J Lai; A John; A Berlin; M H Kaplan; N W Lukacs
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

5.  Cytokines in severe respiratory syncytial virus bronchiolitis.

Authors:  Kevin J Mobbs; Rosalind L Smyth; Una O'Hea; Deborah Ashby; Paul Ritson; C Anthony Hart
Journal:  Pediatr Pulmonol       Date:  2002-06

6.  Cutting Edge: Oseltamivir decreases T cell GM1 expression and inhibits clearance of respiratory syncytial virus: potential role of endogenous sialidase in antiviral immunity.

Authors:  Martin L Moore; Michael H Chi; Weisong Zhou; Kasia Goleniewska; Jamye F O'Neal; James N Higginbotham; R Stokes Peebles
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

7.  Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs.

Authors:  G Piedimonte; M M Rodriguez; K A King; S McLean; X Jiang
Journal:  Am J Physiol       Date:  1999-10

8.  Genetic variability of group A human respiratory syncytial virus strains circulating in Germany from 1998 to 2007.

Authors:  Janine Reiche; Brunhilde Schweiger
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

9.  Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice.

Authors:  B S Graham; L A Bunton; P F Wright; D T Karzon
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

10.  Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5.

Authors:  Koichi Hashimoto; Barney S Graham; Samuel B Ho; Kenneth B Adler; Robert D Collins; Sandra J Olson; Weisong Zhou; Tatsuo Suzutani; Phillip W Jones; Kasia Goleniewska; Jamye F O'Neal; R Stokes Peebles
Journal:  Am J Respir Crit Care Med       Date:  2004-05-06       Impact factor: 21.405

View more
  104 in total

Review 1.  Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma.

Authors:  Amy S Feldman; Yuan He; Martin L Moore; Marc B Hershenson; Tina V Hartert
Journal:  Am J Respir Crit Care Med       Date:  2015-01-01       Impact factor: 21.405

2.  Respiratory syncytial virus infection induces a subset of types I and III interferons in human dendritic cells.

Authors:  Philippa Hillyer; Viraj P Mane; Aaron Chen; Maria B Dos Santos; Lynnsie M Schramm; Rachel E Shepard; Cindy Luongo; Cyril Le Nouën; Lei Huang; Lihan Yan; Ursula J Buchholz; Ronald G Jubin; Peter L Collins; Ronald L Rabin
Journal:  Virology       Date:  2017-01-31       Impact factor: 3.616

3.  Sirtuin 1 Regulates Dendritic Cell Activation and Autophagy during Respiratory Syncytial Virus-Induced Immune Responses.

Authors:  Anna B Owczarczyk; Matthew A Schaller; Michelle Reed; Andrew J Rasky; David B Lombard; Nicholas W Lukacs
Journal:  J Immunol       Date:  2015-07-08       Impact factor: 5.422

4.  Pathogenesis, Humoral Immune Responses, and Transmission between Cohoused Animals in a Ferret Model of Human Respiratory Syncytial Virus Infection.

Authors:  Karen L Laurie; Patrick C Reading; Kok Fei Chan; Louise A Carolan; Julian Druce; Keith Chappell; Daniel Watterson; Paul Young; Daniil Korenkov; Kanta Subbarao; Ian G Barr
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

5.  A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats.

Authors:  Christina A Rostad; Christopher C Stobart; Brian E Gilbert; Ray J Pickles; Anne L Hotard; Jia Meng; Jorge C G Blanco; Syed M Moin; Barney S Graham; Pedro A Piedra; Martin L Moore
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

Review 6.  The impact of viral genotype on pathogenesis and disease severity: respiratory syncytial virus and human rhinoviruses.

Authors:  Martin L Moore; Kate L Stokes; Tina V Hartert
Journal:  Curr Opin Immunol       Date:  2013-12       Impact factor: 7.486

7.  Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice.

Authors:  Sujin Lee; Robert S Mittler; Martin L Moore
Journal:  J Immunol       Date:  2013-11-27       Impact factor: 5.422

8.  Disruption of the airway epithelial barrier in a murine model of respiratory syncytial virus infection.

Authors:  Carrie C Smallcombe; Debra T Linfield; Terri J Harford; Vladimir Bokun; Andrei I Ivanov; Giovanni Piedimonte; Fariba Rezaee
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-11-29       Impact factor: 5.464

9.  Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors.

Authors:  Dan Yan; Sujin Lee; Vidhi D Thakkar; Ming Luo; Martin L Moore; Richard Karl Plemper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

10.  A stabilized respiratory syncytial virus reverse genetics system amenable to recombination-mediated mutagenesis.

Authors:  Anne L Hotard; Fyza Y Shaikh; Sujin Lee; Dan Yan; Michael N Teng; Richard K Plemper; James E Crowe; Martin L Moore
Journal:  Virology       Date:  2012-10-11       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.